← Leaderboards
Natasha M. Nesbitt
Blood Cell Technologies, Llc
$2,689,157
Attributed
$2,689,157
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $764K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,689,157 · 3
By mechanism
R44$2,468,166 · 2
R43$220,991 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Platelet Transfusion”
- Susan Fera Assmann · New England Research Institutes, Inc.$27,762,151
- Mortimer Poncz · University Of Pennsylvania$21,613,220
- Karin Maria Hoffmeister · Versiti Blood Health, Inc.$13,401,766
- Peter J Newman · Bloodcenter Of Wisconsin, Inc.$12,827,480
- Mark Roberts Looney · University Of California, San Francisco$11,860,614
- Bart Barlogie · University Of Arkansas Med Scis Ltl Rock$10,683,504
Research focus
Platelet TransfusionToxic EffectLeadPlatelet Count MeasurementSmall Business Innovation Research GrantThrombopoietinIn VitroIn VivoOxidation-ReductionPharmaceutical PreparationsProductionProgramsTechnologyThrombocytopeniaHematopoieticHemorrhageDesignBlood CellsBiliverdineLinkOxidoreductaseBlood PlateletsAgonistValidation
Grant awards (5)
Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia$400,000
R44 · FY2025 · CA · contact PI
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$613,208
R44 · FY2023 · HL · contact PI
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$763,993
R44 · FY2022 · HL · contact PI
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$690,965
R44 · FY2021 · HL · contact PI
Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production$220,991
R43 · FY2015 · HL · contact PI